"All we are saying [to Novo Nordisk] is, Treat the American people the same way that you treat people all over the world.

Here are five key takeaways: During the hearing, Novo Nordisk CEO Lars Fruergaard Jørgensen attributed the high prices of drugs such as Ozempic and Wegovy to PBMs, arguing that "a high list price is ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...

Sen. Bernie Sanders questions Novo Nordisk CEO Lars Jorgensen in a hearing on Capitol Hill about the high prices Americans pay for Ozempic and Wegovy compared with people in other countries.

Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to ...

Health-care company stocks fell as Novo Nordisk CEO Lars Fruergaard Jørgensen defended the prices of his company's megablockbuster obesity and Type 2 diabetes medicines under tough questioning on ...

Novo Nordisk CEO Lars Fruergaard Jørgensen, however, said that lowering the prices could result in unintended consequences like the drug being dropped completely from insurance companies.

No, if Novo Nordisk lowered their list price for Ozempic and Wegovy tomorrow to a price that was the same or lower than current net cost, that change by itself would not result in less favorable ...

Senators grilled Novo Nordisk CEO Lars Jørgensen Tuesday at a hearing over the costs of Ozempic, Wegovy and similar weight ...

Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on ...